.Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G04B_Urologicals.G04BE08_Tadalafil.Tadalafil

Information

Tadalafil is a selective phosphodiesterase type 5 (PDE5) inhibitor used for the treatment of erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension. It is an orally administered drug, approved and widely used in clinical practice.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult males after a single oral dose administration.

References

1. Trocóniz, IF, et al., & Forgue, ST (2007). Tadalafil population pharmacokinetics in patients with erectile dysfunction. European journal of clinical pharmacology 63(6) 583–590. DOI:10.1007/s00228-007-0297-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17431603

2. Briganti, A, et al., & Montorsi, F (2005). Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction. Nature clinical practice. Urology 2(5) 239–247. DOI:10.1038/ncpuro0186 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16474835

3. Porst, H, et al., & Sharlip, I (2013). SOP conservative (medical and mechanical) treatment of erectile dysfunction. The journal of sexual medicine 10(1) 130–171. DOI:10.1111/jsm.12023 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23343170

Revisions

• 06/2025 initial generated model